Roland Griffiths (1946–2023)
American psychopharmacologist, and the single most important figure in dragging serious psilocybin research back into legitimate science after four decades of prohibition-era silence. If a study cited on this site’s own archived pages traces back to one name more than any other, it’s his.
Roland R. Griffiths earned his bachelor’s degree from Occidental College (1968) and a Ph.D. in psychology from the University of Minnesota (1972), then joined Johns Hopkins University School of Medicine, where he would remain for more than fifty years — first as an assistant professor in behavioral biology, then as research chief of the Department of Psychiatry’s Behavioral Pharmacology Research Unit from 1975 onward. Long before psychedelics entered his work, Griffiths had already built a serious scientific reputation studying caffeine dependence, research rigorous enough that it led to caffeine withdrawal being formally recognized as a clinical condition in the DSM-5 — a useful reminder, in retrospect, that the researcher who eventually made psilocybin respectable again had already spent a career being exactly that kind of careful.
The 2006 study that restarted a field
In 2006, Griffiths published a landmark study in the journal Psychopharmacology showing that a single high dose of psilocybin, given to healthy volunteers under carefully controlled conditions, reliably produced experiences its recipients rated as among the most personally and spiritually significant of their entire lives — comparable, in the structured measures his team used, to experiences reported after the sudden death of a parent or the birth of a child. That paper — the same 2006 Griffiths et al. study already cited on this site’s own archived “The Mushroom” and “Entheogen” pages — is widely credited as the single study that opened the door to the modern psychedelic research renaissance, giving a scientifically unimpeachable foundation to a subject the field had avoided since the 1970s.
He didn’t stop there. Griffiths and his colleagues went on to run studies showing psilocybin could ease existential distress and depression in patients with terminal cancer diagnoses, and in 2020 published, in JAMA Psychiatry, the first rigorous controlled trial demonstrating that psilocybin-assisted psychotherapy could effectively treat clinical depression — a result that helped set the stage for the wave of psilocybin depression research (including the Karolinska and other trials this site has since covered) still unfolding today.
Building an institution
The credibility his research generated translated directly into infrastructure: in 2019, Griffiths became founding director of the Johns Hopkins Center for Psychedelic and Consciousness Research, established with $17 million in donor gifts — the first center of its kind at a major American research university, and a model other institutions have since copied. A later $24 million gift endowed the Roland R. Griffiths, Ph.D. Professorship in his name, described as the largest endowed position in the history of the Johns Hopkins School of Medicine.
Meaning it personally
Griffiths’ interest in these questions wasn’t purely academic. He maintained a dedicated Siddha Yoga meditation practice for some 25 years, and when diagnosed with late-stage colon cancer in November 2021, he approached his own death with the same framework his research had spent decades studying in others — calling the diagnosis itself “a gift,” and describing his own coping strategy as “the cultivation of gratitude for the precious gift of life itself, of being conscious, awake to the mystery of this present moment.” He died October 16, 2023, at 77, having authored more than 400 journal articles and book chapters across his career.
Sources: